Lilly's Zepbound (tirzepatide 10 mg and 15 mg) was associated with more weight loss than Wegovy HD (semaglutide injection 7.2 mg) in a new indirect treatment comparison
Lilly announced new indirect treatment comparison data showing Zepbound 10 mg and 15 mg were associated with greater weight loss than Novo's high-dose Wegovy HD (semaglutide 7.2 mg) in adults with obesity. Zepbound 15 mg showed 4.5% greater weight loss and more than three times the odds of achieving at least 20% body-weight reduction versus Wegovy HD under the treatment-regimen estimand, though efficacy-estimand differences were not statistically significant.
Key figures
- Drug Name
- Zepbound (tirzepatide)
- Phase Of Trial
- indirect comparison of Phase 3 trials (SURMOUNT-1 vs STEP UP)
- Surmount5 relative weight loss
- 47% greater
- Surmount5 wegovy weight reduction
- 13.7%
- Surmount5 zepbound weight reduction
- 20.2%
- Additional weight loss zepbound 10mg
- 3.2%
- Additional weight loss zepbound 15mg
- 4.5%
- Odds ratio 20pct weight loss 15mg efficacy
- 4.15
- Odds ratio 20pct weight loss 15mg treatment regimen
- 3.54
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.